InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.260 0.06 (2.59%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,941 Appendix 3Y for Eric Rose 14 Oct 2025 6:07PM $2.760 $2.260 fallen by 18.12%
$2,941 Becoming a substantial holder 14 Oct 2025 8:21AM $2.820 $2.260 fallen by 19.86%
$2,941 Ryoncil Revenues Increase 66% in Second Quarter Post Launch 7 Oct 2025 9:44AM $2.590 $2.260 fallen by 12.74%
$2,941 Ryoncil Receives CMS (Medicaid) J-Code for Reimbursement 3 Oct 2025 10:03AM $2.630 $2.260 fallen by 14.07%
$2,941 Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs 26 Sep 2025 2:55PM $2.400 $2.260 fallen by 5.83%
$2,941 Ceasing to be a substantial holder 22 Sep 2025 3:52PM $2.520 $2.260 fallen by 10.32%
$2,941 Becoming a substantial holder 16 Sep 2025 6:12PM $2.340 $2.260 fallen by 3.42%
$2,941 Becoming a substantial holder 16 Sep 2025 10:48AM $2.315 $2.260 fallen by 2.38%
$2,941 Ceasing to be a substantial holder 15 Sep 2025 5:44PM $2.320 $2.260 fallen by 2.59%
$2,941 Ryoncil Launch Highlighted at Global Healthcare Conferences 15 Sep 2025 9:59AM $2.210 $2.260 risen by 2.26%
$2,941 Change of Director's Interest Notice 12 Sep 2025 2:22PM $2.225 $2.260 risen by 1.57%
$2,941 Change in substantial holding 12 Sep 2025 1:03PM $2.250 $2.260 risen by 0.44%
$2,941 Proposed issue of securities - MSB 4 Sep 2025 9:56AM $1.940 $2.260 risen by 16.49%
$2,941 Mesoblast Option to Issue up to US$50m Convertible Notes 4 Sep 2025 9:45AM $1.940 $2.260 risen by 16.49%
$2,941 Mesoblast Option to Issue up to US$50m Convertible Notes 4 Sep 2025 9:45AM $1.940 $2.260 risen by 16.49%
$2,941 Becoming a substantial holder 29 Aug 2025 6:39PM $2.180 $2.260 risen by 3.67%
$2,941 MSB Annual Financial Results and Operational Update 29 Aug 2025 8:31AM $2.420 $2.260 fallen by 6.61%
$2,941 MSB Annual Financial Results and Operational Update 29 Aug 2025 8:31AM $2.420 $2.260 fallen by 6.61%
$2,941 Annual Financial Results Presentation 29 Aug 2025 8:26AM $2.420 $2.260 fallen by 6.61%
$2,941 Annual Financial Results Presentation 29 Aug 2025 8:26AM $2.420 $2.260 fallen by 6.61%
$2,941 Preliminary Final Report including Appendix 4E 29 Aug 2025 8:23AM $2.420 $2.260 fallen by 6.61%
$2,941 Mesoblast 2025 Full Year Financial Results Webcast 27 Aug 2025 4:17PM $2.490 $2.260 fallen by 9.24%
$2,941 Ceasing to be a substantial holder 25 Aug 2025 2:34PM $2.455 $2.260 fallen by 7.94%
$2,941 Becoming a substantial holder 29 Jul 2025 7:26PM $2.490 $2.260 fallen by 9.24%
$2,941 Ceasing to be a substantial holder 25 Jul 2025 6:50PM $2.520 $2.260 fallen by 10.32%

126 - 150 of 1201 results

Page 6 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.